|
1
|
Chang H, Wang Q, Shi T, Huo K, Li C, Zhang
Q, Wang G, Wang Y, Tang B, Wang W, et al: Effect of DanQi Pill on
PPARα, lipid disorders and arachidonic acid pathway in rat model of
coronary heart disease. BMC Complement Altern Med. 16:1032016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee VW, Cheng FW, Choi AY, Fong ST, Yu CM
and Yan BP: Clinical, humanistic, and economic outcomes between
drug-eluting stent (DES) and bare metal stent (BMS): 18-month
follow-up study. J Med Econ. 1–7, 31 Oct. 2016.(Epub ahead of
print). View Article : Google Scholar
|
|
3
|
Babapulle MN and Eisenberg MJ: Coated
stents for the prevention of restenosis: Part I. Circulation.
106:2734–2740. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fricker J: Drug-eluting stents: Flashy
future or flash-in-the-pan? Drug Discov Today. 6:1135–1137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Regar E, Sianos G and Serruys PW: Stent
development and local drug delivery. Br Med Bull. 59:227–248. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dilda PJ and Hogg PJ: Arsenical-based
cancer drugs. Cancer Treat Rev. 33:542–564. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J,
Cai X, Han ZG, Ni JH, Shi GY, Jia PM, et al: Use of arsenic
trioxide (As2O3) in the treatment of acute promyelocytic leukemia
(APL): I. As2O3 exerts dose-dependent dual effects on APL cells.
Blood. 89:3345–3353. 1997.PubMed/NCBI
|
|
8
|
Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu
YM, Shi JY, Zheng PZ, Yan H, Liu YF, et al: All-trans retinoic
acid/As2O3 combination yields a high quality remission and survival
in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci
USA. 101:5328–5335. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lo-Coco F, Avvisati G, Vignetti M, Thiede
C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona
E, et al: Retinoic acid and arsenic trioxide for acute
promyelocytic leukemia. N Engl J Med. 369:111–121. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang X, Yang XR, Sun C, Hu B, Sun YF,
Huang XW, Wang Z, He YF, Zeng HY, Qiu SJ, et al: Promyelocytic
leukemia protein induces arsenic trioxide resistance through
regulation of aldehyde dehydrogenase 3 family member A1 in
hepatocellular carcinoma. Cancer Lett. 366:112–122. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hoffman EA, Gizelska K, Mirowski M and
Mielicki W: Arsenic trioxide downregulates cancer procoagulant
activity in MCF-7 and WM-115 cell lines in vitro. Contemp Oncol
(Pozn). 19:108–112. 2015.PubMed/NCBI
|
|
12
|
Liu ZM, Tseng HY, Cheng YL, Yeh BW, Wu WJ
and Huang HS: TG-interacting factor transcriptionally induced by
AKT/FOXO3A is a negative regulator that antagonizes arsenic
trioxide-induced cancer cell apoptosis. Toxicol Appl Pharmacol.
285:41–50. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang W, Ge J, Liu H, Zhao K, Liu X, Qu X,
Li W, Huang Y, Sun A and Zou Y: Arsenic trioxide eluting stent
reduces neointima formation in a rabbit iliac artery injury model.
Cardiovasc Res. 72:483–493. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shen L, Gong F, Tian W, Li W, Zhang F,
Qian J, Sun A, Zou Y, Yang W and Ge J: Anti-inflammatory effects of
arsenic trioxide eluting stents in a porcine coronary model. Biomed
Res Int. 2013:9379362013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li JX, Shen YQ, Cai BZ, Zhao J, Bai X, Lu
YJ and Li XQ: Arsenic trioxide induces the apoptosis in vascular
smooth muscle cells via increasing intracellular calcium and ROS
formation. Mol Biol Rep. 37:1569–1576. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Seldinger SI: Catheter replacement of the
needle in percutaneous arteriography. A new technique. Acta Radiol
Suppl (Stockholm). 434:47–52. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li J, Elrashidi MY, Flammer AJ, Lennon RJ,
Bell MR, Holmes DR, Bresnahan JF, Rihal CS, Lerman LO and Lerman A:
Long-term outcomes of fractional flow reserve-guided vs.
angiography-guided percutaneous coronary intervention in
contemporary practice. Eur Heart J. 34:1375–1383. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
The Thrombolysis in Myocardial Infarction
(TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med.
312:932–936. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Byrne RA, Sarafoff N, Kastrati A and
Schömig A: Drug-eluting stents in percutaneous coronary
intervention: A benefit-risk assessment. Drug Saf. 32:749–770.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shen L, Yang W, Yin JS, Liu XB, Wu YZ, Sun
AJ, Qian JY and Ge JB: Nine-month angiographic and two-year
clinical follow-up of novel biodegradable-polymer arsenic
trioxide-elutin gstent versus durable-polymer sirolimus-eluting
stent for coronary artery disease. Chin Med J (Engl). 128:768–773.
2015. View Article : Google Scholar : PubMed/NCBI
|
